Farmas USA

Yo tuve suerte de pillarla a 5,2

yo la tengo mas arriba en 6.06 asi que habra que esperar ,Jorge A digo que tenia buena pinta asi que esperaremos a ver si cogemos algunas plusvalias "parece tarde para entrar con mas en THDL" va como un cohete estaran cerrando cortos

(RTTNews) - Shares of Endocyte Inc. (ECYT: News ) have gained more than 50 percent in value in less than two weeks as the company gets ready to restart a phase III ovarian cancer trial. The trial, dubbed PROCEED, was halted last year due to shortage of a comparator drug used in the study.

For readers who are new to Endocyte, here's a brief overview of its pipeline and the upcoming events to watch out for...

Endocyte uses its proprietary technology to create novel small molecule drug conjugates or SMDCs, and companion imaging diagnostics - the combination of which is designed to personalize the treatment of cancer and other serious diseases.

The company's lead product candidate is EC145, for the potential treatment of folate receptor-expressing cancers like ovarian and lung cancers. EC145 is a combination of folate (vitamin B9) and a type of anti-cancer drug known as a "vinca", and is designed to target tumors while avoiding healthy cells. This targeted approach aims to provide treatment with super-potent drugs while lowering toxicity compared to standard chemotherapy.

EC20 is the proprietary companion imaging diagnostic for EC145 - i.e. before being administered the therapeutic, EC145, the patients will have a nuclear medicine scan using the investigational imaging agent called EC20.

The most advanced clinical trial of Endocyte - PROCEED, will compare EC145 in combination with Doxil versus Doxil alone in patients with platinum-resistant ovarian cancer. Johnson & Johnson's Doxil is an approved standard therapy for the treatment of women with platinum-resistant ovarian cancer.

Lo de ARNA es de traca +20%

alguien sabe leer las opciones de ARNA para ver si es buen momento de entrar,gracias

http://finance.yahoo.com/q/op?s=ARNA

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) stated its weight-loss drug candidate lorcaserin was accepted for assessment by European regulators and confirmed that a US Food and Drug Administration advisory committee will meet in the Q2 to talk about the firm’s resubmitted application for lorcaserin. Shares added 8.7% at $2.62 premarket.

y no afloja, la perra.Estoy por entrar en una corrección (si se deja).